Dyax (DYAX) Debt-to-Equity : 0.00 (As of Sep. 2015)

View and export this data going back to . Start your Free Trial

What is Dyax Debt-to-Equity?

Dyax's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $0.00 Mil. Dyax's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $0.00 Mil. Dyax's Total Stockholders Equity for the quarter that ended in Sep. 2015 was $314.47 Mil. Dyax's debt to equity for the quarter that ended in Sep. 2015 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Dyax's Debt-to-Equity or its related term are showing as below:

DYAX's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Dyax Debt-to-Equity Historical Data

The historical data trend for Dyax's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyax Debt-to-Equity Chart

Dyax Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Debt-to-Equity

Get a 7-Day Free Trial

21.67

-2.76

-1.54

3.13

0.78

Dyax Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
Debt-to-Equity	Get a 7-Day Free Trial															0.78	0.78	0.81	0.26	-

Competitive Comparison of Dyax's Debt-to-Equity

For the Biotechnology subindustry, Dyax's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dyax's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyax's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Dyax's Debt-to-Equity falls into.

Dyax Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Dyax's Debt to Equity Ratio for the fiscal year that ended in Dec. 2014 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	82.165)	/	105.803
	=	0.78

Dyax's Debt to Equity Ratio for the quarter that ended in Sep. 2015 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	314.469
	=	0.00

Dyax (NAS:DYAX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Dyax Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Dyax's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyax (DYAX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyax Corp (NAS:DYAX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.dyax.com

Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.

Executives

David J Mclachlan	other: Former director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Gustav Christensen	officer: CEO and President, other: Former director	DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Todd Bazemore	officer: EVP & Chief Commercial Officer	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Thomas L Kempner	other: Former director	C/O LOEB PARTNERS CORPORATION, 125 BROAD STREET, 14TH FLOOR, NEW YORK NY 10004
Abbie Celniker	other: Former director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Marc D Kozin	other: Former director
Andrew D. Ashe	officer: General Counsel & EVP	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ron Cohen	other: Former director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Mary Ann Gray	other: Former director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
George V Migausky	officer: EVP & Chief Financial Officer	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Pucci	other: Former director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Burt A Adelman	officer: CMO & EVP, R&D	DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ivana Magovcevic-liebisch	officer: EVP; Chief Operating Officer	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Susan B Bayh	director	WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Stephen S Galliker	officer: EVP and CFO	300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139